Key facts
- Amani Therapeutics’s last known valuation is $44.5M (Mar 2026).
- It has raised $31.1M across 1 recorded rounds; the latest was Early Stage VC ($31.1M) in Nov 2025.
- Notable investors include RTW Investments.
- Amani Therapeutics has filed 1 Form D with the SEC, most recently Dec 2025 ($31.1M sold to 2 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Amani Therapeutics
Funding rounds
1 roundsAbout Amani Therapeutics
Developer of a biotechnology company intended to deliver safer and more effective psychiatric treatments to patients. The company's product includes clozapine for patients with schizophrenia, enabling doctors to reduce suicide risk in patients with schizophrenia and schizoaffective disorder.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2025
- Website
- amanitx.com/
- Ownership
- Privately Held (backing)
Amani Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amani Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amani Therapeutics in its N-PORT filings yet. We sweep new filings monthly.